ALDEYRA THERAPEUTICS, INC. (ALDX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 47.54M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $0.00 | (m) | (m) | (m) | $47.54M | (m) |
| 2026-03-31 | (m) | (m) | $15.30M | $0.00 | (m) | (m) | $66.48M | (m) |
| 2025-12-31 | (m) | (m) | $15.25M | $0.00 | (m) | $70.04M | $72.06M | (m) |
| 2025-09-30 | (m) | (m) | $15.20M | $0.00 | (m) | $75.30M | $77.80M | (m) |
| 2025-06-30 | (m) | (m) | $15.15M | $0.00 | (m) | $81.92M | $84.96M | (m) |
| 2025-03-31 | (m) | (m) | $0.00 | $15.10M | (m) | $90.06M | $93.20M | (m) |
| 2024-12-31 | (m) | (m) | $31.37K | $15.00M | (m) | $101.15M | $104.61M | (m) |
| 2024-09-30 | (m) | (m) | $279.96K | $15.00M | (m) | $112.74M | $117.32M | (m) |
| 2024-06-30 | (m) | (m) | $15.24M | $0.00 | (m) | $120.33M | $126.04M | (m) |
| 2024-03-31 | (m) | (m) | $15.20M | $0.00 | (m) | $133.04M | $141.30M | (m) |
| 2023-12-31 | (m) | (m) | $15.15M | $0.00 | (m) | (m) | $148.33M | (m) |
| 2023-09-30 | (m) | (m) | $13.46M | $2.66M | (m) | (m) | $147.28M | (m) |
| 2023-06-30 | (m) | (m) | $5.89M | $10.13M | (m) | (m) | $155.62M | (m) |
| 2023-03-31 | (m) | (m) | $954.33K | $14.97M | (m) | (m) | $168.22M | (m) |
| 2022-12-31 | (m) | (m) | $911.76K | $14.92M | (m) | $174.30M | $181.29M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $3.30M | (m) | $185.33M | $189.69M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $10.74M | (m) | $196.69M | $201.02M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $15.59M | (m) | $216.87M | $222.69M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $15.50M | (m) | $229.79M | $233.14M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $15.42M | (m) | (m) | $247.22M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $15.34M | (m) | (m) | $256.43M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $10.14M | (m) | (m) | $147.31M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $11.43M | (m) | (m) | $83.35M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $12.69M | (m) | (m) | $88.32M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $13.92M | (m) | $66.19M | $71.63M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $14.67M | (m) | $61.38M | $63.03M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $14.53M | (m) | $73.36M | $75.52M | (m) |
| 2019-09-30 | (m) | (m) | (m) | $14.39M | (m) | $76.17M | $77.44M | (m) |
| 2018-09-30 | (m) | (m) | $465.28K | $882.84K | (m) | $35.14M | $37.13M | (m) |
| 2018-06-30 | (m) | (m) | $348.96K | $995.29K | (m) | $41.68M | $43.29M | (m) |
| 2018-03-31 | (m) | (m) | $232.64K | $1.11M | (m) | $38.94M | $40.78M | (m) |
| 2017-12-31 | (m) | (m) | $116.32K | $1.22M | (m) | $42.95M | $44.17M | (m) |
| 2017-09-30 | (m) | (m) | $426.50K | $905.25K | (m) | $47.91M | $49.23M | (m) |
| 2017-06-30 | (m) | (m) | $310.19K | $1.02M | (m) | $25.82M | $26.47M | (m) |
| 2017-03-31 | (m) | (m) | $193.87K | $1.13M | (m) | $31.21M | $31.53M | (m) |
| 2016-12-31 | (m) | (m) | $77.55K | $1.24M | (m) | $24.91M | $25.19M | (m) |
| 2016-09-30 | (m) | (m) | $426.50K | $883.28K | (m) | $28.88M | $29.19M | (m) |
| 2016-06-30 | (m) | (m) | $310.19K | $992.63K | (m) | $32.55M | $32.88M | (m) |
| 2016-03-31 | (m) | (m) | $193.87K | $1.10M | (m) | $23.03M | $23.44M | (m) |
| 2015-12-31 | (m) | (m) | $77.55K | $1.21M | (m) | $27.59M | $28.20M | (m) |
| 2015-09-30 | (m) | (m) | (m) | $1.28M | (m) | (m) | $31.35M | (m) |
| 2015-06-30 | (m) | (m) | $310.19K | $961.55K | (m) | (m) | $33.88M | (m) |
| 2015-03-31 | (m) | (m) | $193.87K | $1.07M | (m) | (m) | $15.93M | (m) |
| 2014-12-31 | (m) | (m) | $77.55K | $1.18M | (m) | (m) | $8.79M | (m) |
| 2014-09-30 | (m) | (m) | (m) | $1.24M | (m) | (m) | $10.35M | (m) |
| 2014-06-30 | (m) | (m) | $407.12K | $815.83K | (m) | (m) | $11.81M | (m) |
| 2014-03-31 | (m) | (m) | $232.64K | $972.42K | (m) | (m) | $2.89M | (m) |
| 2013-12-31 | (m) | (m) | $58.16K | $1.13M | (m) | (m) | $3.74M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |